Summary
To assess bezafibrate efficacy in a diabetic population a single-blind randomized
study was performed in 32 diet-resistant type IIb hyperlipidaemic non-insulin-dependent
(NID) diabetic patients in good metabolic control (HbA1c<8%) compared to a placebo group. In our diabetic patients one month treatment of
400 mg/day bezafibrate lowered plasma C (-14%) and TG (-37%) and globally reduced
the VLDL particles and VLDL lipids (-37% for C, -56% for TG and -25% for PL), raising
VLDL C/TG ratio (+46%), redistributing TG from VLDL to LDL (+10%) and mainly in HDL
(+49%), lowered LDL-C and Apo B levels and increased HDL-C together with Apo A1 (+19%
and +13%) and Apo Al/Apo B (+72%). PL were raised by bezafibrate treatment and were
redistributed from VLDL (-25%) to LDL (+25%) and HDL (+18%), while PL/C ratio increased
in VLDL and in LDL (+18% and +50% respectively). Bezafibrate use was safe and improved
the lipid pattern and the apolipoprotein and lipid distribution in the lipoproteins,
producing a less atherogenic pattern in our NID diabetics.
Key words
Non-Insulin-Dependent Diabetes - Bezafibrate - Hyperlipidemia
